Advancing Real-World Effectiveness Evidence for Rapid-Acting Psychotropic Interventional Drugs (RAPIDs) (UM1 Clinical Trial Required)
National Institutes of Health
Want a reminder before this closes?
We'll email you 3 days before the deadline. One email, then we stop.
Free. Verify your email, then we send one reminder only.
- Posted
- Sep 16, 2026
- Closes
- Jun 10, 2027 (in 209 days)
Similar opportunities open now
- Early Stage Testing of Pharmacologic or Neuromodulatory Device-based Interventions for the Treatment of Mental Disorders (R33- Clinical Trial Required)Same funderOpenNational Institutes of HealthCloses Oct 2027
- Early Stage Testing of Pharmacologic or Neuromodulatory Device-based Interventions for the Treatment of Mental Disorders (R61/R33 Clinical Trial Required)Same funderOpenNational Institutes of HealthCloses Oct 2027
- Effectiveness Trials to Test Mental Health System Interventions (R61/R33 Clinical Trial Required)Same funderOpenNational Institutes of HealthCloses Oct 2027
- Effectiveness Trials for Post-Acute Interventions and Services to Optimize Longer-term Outcomes (R01 Clinical Trial Required)Same funderOpenNational Institutes of HealthCloses Jan 2028
- Pilot and Feasibility Studies in Preparation for Substance Use and HIV Prevention Intervention and Services Research Trials (R34 Clinical Trial Optional)Same funderOpenNational Institutes of HealthCloses Jul 2029Up to $450K
Classification and identifiers
- Solicitation number
- RFA-MH-27-150
- Assistance listing (CFDA)
- 93.24R
Amount
Amount not listed here. Check the official program.
Who can apply
Private colleges and universities, Local government agencies, and Small businesses can all apply here. Check the eligibility details below to see if your organization fits.
Other Eligible ApplicantsIndian/Native American Tribal Governments (Other than Federally Recognized);Eligible Agencies of the Federal Government;U.S. Territory or Possession;Faith-based or Community-based Organizations;Regional Organizations…
About this opportunity
The National Institute of Mental Health (NIMH) intends to publish a Notice of Funding Opportunity (NOFO) to support the development of a research network to study rapid-acting psychotropic interventional drugs (RAPIDs), such as ketamine, esketamine, psilocybin, and other emerging treatments for serious mental illnesses. Preliminary studies suggest that RAPIDs can produce clinically meaningful improvements in mental health outcomes, in some cases following a single dose. However, important questions remain regarding their effectiveness, safety, durability of benefit, and implementation in routine clinical practice. As these interventions move toward broader use, rigorous real-world evidence is needed to identify how RAPIDs can be delivered safely, effectively, and sustainably across diverse...